A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
← catalyst calendarSponsored by NextCure, Inc. (industry) · NXTC — their whole pipeline →. With Merck Sharp & Dohme LLC.
Phase
Phase 1/2
Status
Terminated
Study type
Interventional
Design
Na · None · Treatment
Enrollment
97actual
Sites
17
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-10-06 | actual | When the study began enrolling |
| Primary completion | 2025-04-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-04-30 | actual | The whole study's end, after follow-up |
| First posted | 2022-10-10 | actual | When this record first appeared on the registry |
| Results posted | 2026-08-13 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced or Metastatic Solid Tumors
- Microsatellite Instability Low
- Microsatellite Instability High
- Microsatellite Stable
- Ovarian Cancer
- Gastric Cancer
- Colo-rectal Cancer
- Esophageal Cancer
- Endometrial Cancer
- Head Neck Cancer
- Cervical Cancer
- Lung Cancer
Interventions
- Drug: NC410
- Drug: pembrolizumab — also filed as KEYTRUDA®
Primary outcome
what the primary-completion date above is the date OFNumber of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0
measured From enrollment through up to 90 days after end of treatment, an average of 1 year
Posted documents
hosted by the registry — we link, never re-serveStudy Protocol and Statistical Analysis Planposted 2024-04-23 · 2.0 MB · Prot_SAP_000.pdf
Permalink · NXTC's whole pipeline · Catalyst calendar · Every registered study · What changed